[Contrast echo imaging on the breast and thyroid cancers].
The utility of ultrasound color Doppler flow mapping imaging for the differential diagnosis on the breast and thyroid tumors had already reported in 1991. Ultrasound contrast agent, SH/TA 508 (Levovist; Schering AG, Germany), had already finished clinical trials in Japan and reported the result phase II, III. On the breast and thyroid lesions, the utility of this contrast agent are safety and usefulness for the accurate diagnosis by the ultrasound color Doppler examination. Throughout of these clinical trials, a quit new ultrasound Doppler imaging methods had been developed, Harmonic Imaging and acoustic emission mode. As the result, ultrasound contrast agent is useful not only for the conventional color Doppler diagnosis but also for the developing of new diagnostic imaging methods.